Geron Corporation's management will present at several upcoming investor conferences in March 2026.
Quiver AI Summary
Geron Corporation, a biopharmaceutical company focused on transforming blood cancer treatment, has announced that its management team will present at several upcoming investor conferences. They will participate in the TD Cowen 46th Annual Healthcare Conference on March 2, the Barclays 28th Annual Global Healthcare Conference on March 10, and the Leerink Partners Global Healthcare Conference on March 11. A live and archived audio webcast of these presentations will be available on Geron's website. The company is known for its first-in-class telomerase inhibitor RYTELO® (imetelstat), which is approved for treating certain patients with low-risk myelodysplastic syndromes. Geron is also conducting a pivotal Phase 3 trial of imetelstat for another condition, aiming to inhibit malignant cell growth by targeting telomerase activity.
Potential Positives
- Geron Corporation is increasing its visibility and engagement with investors through presentations at multiple prestigious healthcare conferences, which can enhance investor confidence and interest.
- The company has a commercially approved product, RYTELO® (imetelstat), for treating specific blood cancer patients, demonstrating its innovative position in the biopharmaceutical market.
- Geron is advancing its research with a pivotal Phase 3 clinical trial for imetelstat, highlighting its commitment to developing effective treatments for hematologic malignancies.
- The press release emphasizes Geron's focus on changing the course of blood cancer, aligning the company's mission with a significant and critical healthcare need.
Potential Negatives
- e
FAQ
What investor conferences will Geron Corporation attend in March 2026?
Geron Corporation will attend the TD Cowen 46th Annual Healthcare Conference, Barclays 28th Annual Global Healthcare Conference, and Leerink Partners Global Healthcare Conference.
When is Geron’s presentation at the TD Cowen Healthcare Conference?
Geron’s presentation at the TD Cowen Healthcare Conference is scheduled for March 2, 2026, at 1:10 p.m. ET.
Where can I find the audio webcasts of Geron’s conferences?
The live and archived audio webcasts will be available in the Investors & Media section of Geron’s website at www.geron.com.
What is RYTELO® and its purpose?
RYTELO® (imetelstat) is a first-in-class telomerase inhibitor approved for certain adult patients with LR-MDS and transfusion-dependent anemia.
What other clinical trials is Geron conducting?
Geron is conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF and studies in other hematologic malignancies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GERN Insider Trading Activity
$GERN insiders have traded $GERN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $GERN stock by insiders over the last 6 months:
- MICHELLE ROBERTSON (EVP, CHIEF FINANCIAL OFFICER) sold 9,855 shares for an estimated $19,118
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GERN Hedge Fund Activity
We have seen 88 institutional investors add shares of $GERN stock to their portfolio, and 154 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 9,606,217 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $13,160,517
- DEEP TRACK CAPITAL, LP removed 8,585,251 shares (-20.9%) from their portfolio in Q4 2025, for an estimated $11,332,531
- MILLENNIUM MANAGEMENT LLC removed 6,764,113 shares (-59.5%) from their portfolio in Q4 2025, for an estimated $8,928,629
- STEMPOINT CAPITAL LP removed 6,649,244 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,109,464
- SOLEUS CAPITAL MANAGEMENT, L.P. added 6,000,000 shares (+34.7%) to their portfolio in Q4 2025, for an estimated $7,920,000
- VESTAL POINT CAPITAL, LP removed 5,905,000 shares (-34.3%) from their portfolio in Q4 2025, for an estimated $7,794,600
- CITADEL ADVISORS LLC removed 5,779,282 shares (-36.8%) from their portfolio in Q4 2025, for an estimated $7,628,652
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:
-
TD Cowen 46th Annual Healthcare Conference
Fireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MA
-
Barclays 28th Annual Global Healthcare Conference
Fireside Chat on Tuesday, March 10 at 10:30 a.m. ET in Miami, FL
-
Leerink Partners Global Healthcare Conference
In-Person Meetings on Wednesday, March 11 in Miami, FL
A live and archived audio webcast of each fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO
®
(imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit
www.geron.com
or
LinkedIn
.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]
